Journal article
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
Authors
Hughes TP; Leber B; Cervantes F; Spector N; Pasquini R; Clementino NCD; Schwarer AP; Dorlhiac-Llacer PE; Mahon F-X; Rea D
Journal
Leukemia, Vol. 31, No. 11, pp. 2529–2531
Publisher
Springer Nature
Publication Date
November 1, 2017
DOI
10.1038/leu.2017.247
ISSN
0887-6924